View Item
- xmlui.general.dspace_homeCentros e Institutos de InvestigaciónCICVyA. Centro de Investigación en Ciencias Veterinarias y AgronómicasInstituto de VirologíaArtículos científicosxmlui.ArtifactBrowser.ItemViewer.trail
- DSpace Home
- Centros e Institutos de Investigación
- CICVyA. Centro de Investigación en Ciencias Veterinarias y Agronómicas
- Instituto de Virología
- Artículos científicos
- View Item
Development of a platform process for the production and purification of single‐domain antibodies
Abstract
Single-domain antibodies (sdAbs) offer the affinity and therapeutic value of conventional antibodies, with increased stability and solubility. Unlike conventional antibodies, however, sdAbs do not benefit from a platform manufacturing process. While successful production of a variety of sdAbs has been shown in numerous hosts, purification methods are often molecule specific or require affinity tags, which generally cannot be used in clinical manufacturing
[ver mas...]
Single-domain antibodies (sdAbs) offer the affinity and therapeutic value of conventional antibodies, with increased stability and solubility. Unlike conventional antibodies, however, sdAbs do not benefit from a platform manufacturing process. While successful production of a variety of sdAbs has been shown in numerous hosts, purification methods are often molecule specific or require affinity tags, which generally cannot be used in clinical manufacturing due to regulatory concerns. Here, we have developed a broadly applicable production and purification process for sdAbs in Komagataella phaffii (Pichia pastoris) and demonstrated the production of eight different sdAbs at a quality appropriate for nonclinical studies. We developed a two-step, integrated purification process without the use of affinity resins and showed that modification of a single process parameter, pH of the bridging buffer, was required for the successful purification of a variety of sdAbs. Further, we determined that this parameter can be predicted based only on the biophysical characteristics of the target molecule. Using these methods, we produced nonclinical quality sdAbs as few as 5 weeks after identifying the product sequence. Nonclinical studies of three different sdAbs showed that molecules produced using our platform process conferred protection against viral shedding of rotavirus or H1N1 influenza and were equivalent to similar molecules produced in Escherichia coli and purified using affinity tags.
[Cerrar]
Author
Crowell, Laura E.;
Goodwine, Chaz;
Sosa Holt, Carla Solange;
Rocha, Lucía Alejandra;
Vega, Celina Guadalupe;
Rodriguez-Aponte, Sergio A.;
Dalvie, Neil C.;
Tracey, Mary Kate;
Puntel, Mariana;
Wigdorovitz, Andres;
Parreño, Gladys;
Love, Kerry R.;
Cramer, Steven M.;
Love, J. Christopher;
Fuente
Biotechnology and Bioengineering 118 (9) : 3348-3358. (September 2021)
Date
2021-09
Editorial
Wiley
ISSN
1097-0290
Formato
pdf
Tipo de documento
artículo
Palabras Claves
Derechos de acceso
Abierto
Excepto donde se diga explicitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)